NDAORALSOLUTION
Approved
Nov 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
4/8 — Partial
ROCALTROL (calcitriol) by AbbVie is clinical pharmacology man's natural supply of vitamin d depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin d 3 (cholecalciferol). First approved in 1998.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROCALTROL (calcitriol) is the active form of vitamin D3, a hormone regulator of calcium and phosphorus metabolism. It is indicated for chronic kidney disease, secondary hyperparathyroidism, vitamin D deficiency, osteoporosis, psoriasis, and multiple other bone and metabolic disorders. The drug works by binding to calcitriol receptors in the intestine and bone to stimulate calcium absorption and regulate parathyroid function.
$37KPart D
LOE ApproachingThis legacy product is approaching loss of exclusivity with minimal Part D spending ($37K in 2023), signaling a small, stable team focused on retention rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Man's natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D 3 (cholecalciferol). Vitamin D 3 must be metabolically activated in the liver and the kidney before it is fully…
Worked on ROCALTROL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.